Nirogacestat Shows Promise in Phase 3 Trial for Desmoid Tumors FDA Grants Priority Review

SpringWorks Therapeutics has made a recent announcement regarding the Phase 3 DeFi trial of Nirogacestat in adults with desmoid tumors. The 2023 ASCO Annual Meeting presented additional data from the study, which is the largest trial to date to evaluate volumetric MRI and T2 hyperintensity results in patients with desmoid tumors. The trial has shown significant improvement in progression-free survival, as well as substantial reductions in pain, symptom burden, physical function, and quality of life. Multiple assessment tools have demonstrated that Nirogacestat treatment resulted in rapid, sustained, and consistent reductions in pain compared to the placebo. Additionally, Nirogacestat has shown substantial reductions in MRI-assessed tumor volume and T2 hyperintensity compared to the placebo. Based on the findings from the Phase 3 DeFi trial, the FDA has granted priority review to Nirogacestat for desmoid tumors.

SWTX Stock Analysis: Stable Performance with Low Volume – Keep an Eye on Upcoming Earnings Report

On May 25, 2023, SWTX stock opened at 31.63, slightly lower than the previous close of 32.27. Throughout the day, the stock fluctuated within a range of 29.86 to 31.63. The day’s volume was 16,797, which is significantly lower than the average volume of 839,724 over the past three months.

SWTX is a Health Technology company in the Pharmaceuticals: Major industry with a market cap of $1.9B. The company’s earnings growth last year was -45.17%, but it is expected to increase by 1.69% this year and by 17.84% over the next five years. However, the company did not report any revenue growth last year.

The P/E ratio and Price/Sales for SWTX are not available, but the Price/Book is 3.40. The company does not have any competitors’ data available for comparison.

SWTX’s next reporting date is August 3, 2023, and the EPS forecast for this quarter is -$1.26. The company had an annual revenue of $0.00 and an annual loss of -$277.4M last year. The net profit margin is not available.

Overall, SWTX’s stock performance on May 25, 2023, was relatively stable, but the low volume may indicate a lack of investor interest. Investors may want to keep an eye on SWTX’s upcoming earnings report in August to see if the company can turn its financials around.

SpringWorks Therapeutics Inc: Analysts Target Price of $45.00 with Consensus to Buy Stock

On May 25, 2023, SpringWorks Therapeutics Inc (SWTX) had a median target price of $45.00, according to six analysts who offered 12-month price forecasts. The current consensus among seven polled investment analysts was to buy stock in SpringWorks Therapeutics Inc. SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company that develops innovative medicines for patients with severe diseases. Its lead product candidate is nirogacestat, a gamma-secretase inhibitor for the treatment of desmoid tumors. Despite the negative earnings per share of -$1.26 and zero sales in the current quarter, investors remained optimistic about the company’s future prospects. The stock had been performing well in the past year, with a 52-week range of $17.36 to $45.84. The stock had a market capitalization of $1.62 billion, with 54.08 million outstanding shares.

Read more here: Source link